7/15 affected individuals have somatic reversion. Cannot emphasise this enough- sample type matters!! Fascinating expansion of MECOM phenotype- surprising variability. Lesson- keep open mind! Fab work Scott_lab_GMP LucyCFox Anna Brown Parvathy Venugopal Peer Arts et al 👏

Excited to share our latest publication delving into MECOM-associated syndrome. Huge thanks to all the co-authors Scott_lab_GMP Chris Hahn Peer Arts LucyCFox Annet Simons Anna Brown @Devendrahiwase Centre for Cancer Biology Unisa #fightlikemaddie #raredisease
ashpublications.org/bloodadvances/…

Just launched: Cancer Luminaries, a podcast discussing the past, present and future of cancer research in honor of our 50 yrs of NCI designation. Our first two episodes feature Todd Golub and Otis Brawley. ow.ly/xw9f50RpgtL #UChiCancer50 Johns Hopkins Kimmel Cancer Center Broad Institute

I am thrilled that today, we opened a brand new micro-hospital in Crown Point, Northwest Indiana. UChicagoCancerCenter will offer world-class cancer care to residents of the region close to home. #NothingWillStopUs #WeAreNCIDesignated UChicagoCancerCenter
Kunle Odunsi, MD

Happy #DNADay24 ! It truly is the perfect date.

Shout out to Human Genetics @ UChicago first year grad student, Henry Raeder, for taking the charge on this! Major implications for this general drug class. The article discusses implications for this mechanism of action moving forward.

Until universal germline testing becomes available, Torres-Esquiu has a Q&A: should we enrich the routine myeloid NGS panel with some predisposition genes for patients without germline test indication?. Thanks to gesmd centres onlinelibrary.wiley.com/doi/10.1111/bj…

SNEAK PEEK! Get a behind-the-scenes preview of the brand-new UChicago Medicine Crown Point multispecialty care center, which opens April 29! Dr. blase polite, physician-in-chief of Northwest Indiana, shares what this means for cancer patients who live in the community! #AtTheForefront

Important work! Advancements by Drs. Michael Drazer, Greg Roloff & University of Chicago Hematology/Oncology in expedited HHM diagnostics for #stemcelltransplants are particularly crucial for bone marrow failure patients. This work impacts  #RUNX1FPD by defining a workflow that speeds HHM diagnosis prior to…

What happens when germline predisposition and BMT collide? There often isn’t enough time for donor germline eval before allo. We developed an institutional roadmap with some novel, practical diagnostic maneuvers University of Chicago Hematology/Oncology. Michael Drazer Mariam Nawas

haematologica.org/haematologica/…

This is so cool - a remarkably frequent mutation in a non-protein-coding RNA gene, which causes around one in every 200 currently undiagnosed cases of developmental delay around the world (including 8 Australian families so far!). A couple of thoughts (1/3)

Congratulations to Data for the Common Good (home of the PCDC) team on winning prestigious 'White House's OSTP Year of Open Science Recognition Challenge award' for creating the world’s largest international sharing platform for data from kids with cancer.
White House Office of Science & Technology Policy UChicagoCancerCenter
ow.ly/MEr650R3g2Q

The Dept. of Pathology at the University of Chicago is hiring full-time faculty members to serve as Director and Asst Director of the Transplant Immunology and Immunogenetics Laboratory

Learn more/apply at:
apply.interfolio.com/140784
apply.interfolio.com/139691
EOE/Vet/Disability

A coaches job is to develop people

That's the secret to the great coaches

Their job isn't winning. That's an effect

Why? Obsessive focus on the outcome shifts your motivation & perspective. You stop seeing athletes as people & you treat them accordingly. They stop developing..

Out today in Nature Biotechnology! PhD students & postdocs: there's a trick – overlooked and underused – for having new ideas in the creative process. Talk science 1 on 1 with a science buddy that you trust and think of it as an improvisation. nature.com/articles/s4158……
Martin Lercher

Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline

🔹️ BRCA1/2 testing recommended for newly diagnosed breast cancer patients aged ≤65 and select cases >65

🔹️ Recurrent breast cancer patients eligible for PARP inhibitor therapy…

So excited to see our study finally out in Blood Journal ! Huge thanks to all of our patients who made it possible - and who continue to teach us new things about this disease everyday.